-
Mtech Access
We’re excited to announce that Mtech Access is now Powered by PetauriTM
A purpose-built pharmaceutical-services platform, Petauri is actively partnering with best-in-class companies recognised for their expertise in global market access, health systems, medical affairs, HEOR, patient services, and data and analytics.
As part of Petauri, Mtech Access will offer broader expertise to seamlessly support our valued clients with impactful solutions that speed patient access to life-changing care. Find more details here.
Strategic partners for key market access milestones
We partner with market access and HEOR teams across all global and local milestones, providing the strategy, insight, evidence, and materials to ensure commercial success.
Phase 2
Is there a market for this product? Is there likely to be a return on investment of clinical trials? What is the reimbursement potential?
Recommended approach:
- Opportunity assessment
- Competitor landscape analysis
- Payer landscape analysis
- Price and reimbursement potential analysis
- Early health economic evaluation and modelling
Outcome: Decision-making and the foundations of future market access supported by evidence and strategic insight.
Phase 2-3
What is the strategy to take this product to market? Where and how can we launch? What is our global pricing and reimbursement strategy?
Recommended approach:
- Market analysis (including competitor landscape analysis, insights from analogous products, and analysis of prior health technology assessment (HTA) or reimbursement decisions)
- Target product profile testing
- Price benchmarking and testing
- Market access strategy development
- Evidence generation plan development
- Competitor defence strategy
Outcome: A comprehensive strategy for global market access that is driven by market, competitor, and payer insights.
Phase 3 to launch
Do we have the value messaging and evidence to secure reimbursement in key markets?
Recommended approach:
- Value proposition development (with payer validation)
- Evidence synthesis via systematic literature review, network meta-analysis, and/or indirect treatment comparisons
- Health economic models (e.g. cost-effectiveness model and budget impact model)
- Value dossier and objection handler
- Hosting of materials on global value platform
- Publication strategy and development
- Roll out of global value materials to local affiliates and support with local adaptation for key markets
Outcome: Impactful messaging, value materials, and evidence ready for local affiliates launches.
Phase 3 to launch and beyond
How do we secure HTA recommendations across the UK and Ireland?
Recommended approach:
- Evidence review and gap analysis, review or development of health technology assessment (HTA) strategy
- Starting in England: National Institute for Health and Care Excellence (NICE) HTA submission – full HTA support, including systematic literature reviews (clinical and economic), cost-effectiveness models (CIMs) and budget impact models (BIMs), advisory boards, expert elicitation, submission dossiers, and post-NICE submission services, such as mock meetings and scenario analysis
- Moving to Scotland: Scottish Medicines Consortium (SMC) submission – adaptation of NICE submission to meet SMC requirements (e.g. update of CEMs and BIMs) and incorporation of key learns from NICE submission and any newly published evidence
- Then to Ireland: National Centre for Pharmacoeconomics (NCPE) submission adaptation of NICE/SMC dossiers to meet NCPE requirements (e.g. update of BIMs) and key learns
- Commercial launch plan review – sharing learnings from HTA process for local market access teams
Outcome: Robust HTA strategies and submissions to secure approval in these key markets.
How do we launch this product in the key local market? What do we need to engage local payers?
Recommended approach:
- Development of launch strategy
- Review and analysis of global value materials and re-development for local market
- Ad board with local key opinion leaders
- Above-brand ‘case for change’ messaging
- Localised value propositions/narrative
- Localised economic modelling (e.g. budget impact model)
- Leave pieces/guidelines influencing pieces
- Price negotiation strategy and training
- Objection handling
- User guides for materials
Outcome: Comprehensive local market access strategy and engagement tools to support field team communication with local payers.
How do we navigate the UK healthcare system? What do we need to engage NHS decision-makers and drive change?
Recommended approach:
Recommended approach for launching in key local markets, plus…
- Service assessment and re-design support
- Advanced notifications/advanced budgetary planning
- Workshops on understanding the NHS environment
- Costed patient pathways
- Pre-launch field team training
- NHS stakeholder mapping
- Support and training on how to engage with different operational, strategic, and clinical stakeholders across the NHS
- Specific support for key NHS policies, e.g. specialised commissioning
Outcome: Strategy and insights needed to successfully engage NHS decision-makers and drive change.
We provide strategy and solutions to help Pharma and Medtech companies bring interventions to market, providing more patient choice and meeting the needs of the healthcare environment.
Our consultants and technical experts support global teams and affiliates throughout the product life cycle, from evidence generation and strategy to communication of value.
We support international market access teams in these key launch markets
United Kingdom
Germany
France
Italy
Spain
Canada
USA
Australia
China
Japan
CASE STUDY
Delivering on global market access strategy, evidence generation and communication objectives
Our client’s global market access team were looking for a consultancy who could support them from strategy to implementation. As the client was in the early stages of developing a new product, they first wanted to understand the challenges and opportunities that their new treatment would face when launching in different markets.
Get in touch
View our client testimonials
Download our Mtech Access Brochures
Download a PDF brochure and share the Mtech Access story with colleagues
To discuss your requirements with our experts, get in touch using the form below.
Latest news
At Mtech Access we are always striving to engage with the wider market access community and share our thoughts on the latest industry issues or methods development.
In this four-part series, we will explore the various challenges facing orphan medicines entering the European market and suggest solutions that can help improve patient access. In the final part...
Read More
Challenges for orphan medicines entering the European market – Part 3: Economic evidence development
In this four-part series, we will explore the various challenges facing orphan medicines entering the European market and offer solutions that can help improve patient access. In Part 3 of...
Read More
Challenges for orphan medicines entering the European market – Part 2: Clinical evidence development
In this four-part series, we will explore the various challenges facing orphan medicines entering the European market and offer solutions that can help improve patient access. In Part 2 of...
Read More
In this four-part series, we will explore the various challenges facing orphan medicines entering the European market and offer solutions to help improve patient access. In Part 1, we will...
Read More